Registry of Outcomes of Dezawa MuseCells®

NCT07645989 | Recruiting

• 1 other identifier: Protocol Version 1.2
• Study Type: observational
• Target: 5,000
• Locations: 2 countries
• Sites: 2

Brief Summary

The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases. The Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.

Conditions

Osteoarthritis (OA); Longevity; Wound Care; Pain; Orthopaedic

Keywords

Muse Cells; stem cells; pain; wound; inflammation

Outcome Measures

Primary Outcomes (1)

• Change in Patient Reported Symptom Severity

  Change in condition-specific symptom severity following Dezawa MuseCell® administration.

  Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.

Secondary Outcomes (1)

• Incidence of Treatment-Related Adverse Events (AEs)

  Baseline through 5 years

Other Outcomes (1)

• Long-Term Functional Improvement

  Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.

Study Arms (4)

Orthopaedic

Patients undergoing treatment for orthopaedic conditions

Other: MuseCell Treatment

Longevity

Patients undergoing treatment for longevity and inflammation

Other: MuseCell Treatment

Wound Care

Patients undergoing treatment to treat wounds

Other: MuseCell Treatment

Pain

Patients undergoing treatment for various pain conditions

Other: MuseCell Treatment

Interventions

MuseCell Treatment OTHER

Patients undergoing treatment with Dezawa MuseCells

Longevity; Orthopaedic; Pain; Wound Care

Eligibility Criteria

• Age: Up to 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who have undergone treatment with Dezawa MuseCells

You may qualify if:

• Received Dezawa MuseCells® as Part of Routine Clinical Care
• Patients ( and/or authorized representative) capable of providing informed consent and participating in long-term follow-up.
• Willingness to Complete Online Survey Assessments
• Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.
• Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.
• Ability to Communicate in the Registry's Supported Language
• Participants must be able to read and respond to registry surveys in the designated study language.
• Enrollment Within 12 Months of MuseCell® Administration

You may not qualify if:

• Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit/non-licensed product cannot be included.
• Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.
• Inability to Participate in Long-Term Digital Follow-Up
• Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes
• History of Malignancy Diagnosed Within the Past 12 Months
• Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.
• Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality
• Use of Non-Licensed or Counterfeit "Muse-like" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.
• Pregnant or Actively Breastfeeding at Time of Enrollment

Sponsors & Collaborators

• MuseCell Innovations Pte LTD: lead

Study Sites (2)

Bioreset Medical

North Palm Beach, Florida, 33408, United States

RECRUITING

Regene Labs

Guadalajara, Mexico

RECRUITING

MeSH Terms

Conditions

Osteoarthritis; Pain; Wounds and Injuries; Inflammation

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Pathologic Processes

Central Study Contacts

MuseCell Information

CONTACT

+65 80166929; info@musecellinnovations.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 4, 2025
• First Posted: June 12, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2031
• Study Completion (Estimated): December 31, 2031
• Last Updated: June 12, 2026

Record last verified: 2026-06

Locations

ME (1); US (1)